Zepbound Lawsuit: Two Different Fights, No Settlement Yet
Questions about this case?
AI Legal Assistant · free · answers in seconds · general information, not legal advice
The Zepbound lawsuit you are hearing about is one of two things. Patients who say Eli Lilly’s tirzepatide shot caused stomach paralysis, bowel blockage or vision loss are suing in federal court in Philadelphia, and a hearing on the plaintiffs’ expert evidence was set for September 14–18, 2026. Separately, people whose employer health plans stopped covering Zepbound are suing CVS Caremark — and in August 2026 a New York judge let that case move forward. As of October 5, 2026, there is no Zepbound settlement and no claim form.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Lawsuits Say
Injury cases against Eli Lilly. Since August 2023, patients have sued Lilly and Novo Nordisk over GLP-1 drugs including Mounjaro, Trulicity and Zepbound. The lawsuits allege the companies did not adequately warn about gastrointestinal injuries such as gastroparesis (“stomach paralysis”) and bowel obstruction, and a second group alleges a link to a sudden form of vision loss called NAION. Lilly is defending the cases.
Coverage case against CVS Caremark. The class action complaint alleges that Caremark signed a rebate agreement with Novo Nordisk for Wegovy and, as part of it, stopped covering Zepbound on July 1, 2025. It argues that Zepbound is not interchangeable with Wegovy — Zepbound has been FDA-approved since December 20, 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity, and Wegovy is not — and that denying it to protect rebate income was self-dealing under ERISA, the federal law for employer health plans. Lilly is not a defendant in that case.
Case Details
Injury cases (stomach and bowel): In re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, No. 2:24-md-03094, U.S. District Court for the Eastern District of Pennsylvania, Judge Karen S. Marston (court orders).
Injury cases (vision loss): a separate MDL No. 3163 for NAION claims, same court and judge. Lilly also reports similar cases in Delaware, Indiana and New Jersey state courts, plus two class action petitions in Israel and two in Canada.
Coverage case: Larkin v. Caremark Rx, L.L.C., No. 1:25-cv-07307, U.S. District Court for the Southern District of New York, Judge Louis L. Stanton, filed September 3, 2025 (complaint, PDF).
Status: Expert Ruling Pending, Coverage Case Survives
Caremark case: past the first hurdle. In an order reported by Bloomberg Law on August 27, 2026, Judge Stanton found the plaintiffs had validly alleged that Caremark broke the terms of their health plans and engaged in self-dealing. That means the case continues; it is not a finding that Caremark did anything wrong, and no class has been certified.
Also in the background: Lilly has sued telehealth sellers of compounded tirzepatide (since April 2025) and, in July 2026, received notice of generic-drug applications for Mounjaro and Zepbound. Those are business disputes; they pay nothing to patients.
Follow this case
There's no claim deadline yet. We'll email you if a settlement opens a claim period.
Which Case, If Any, Fits You
If you were injured: the injury cases are individual lawsuits gathered in an MDL, not a class action. Nobody is included automatically — each person files their own case, usually through a lawyer, and must show a diagnosis such as gastroparesis, bowel obstruction or NAION after using the drug. Filing deadlines (statutes of limitations) are set by state law and can run out, so this is the group for whom timing matters most.
If your coverage was denied: the Caremark complaint proposes a class of members of ERISA employer health plans that use Caremark as pharmacy benefit manager, whose Zepbound coverage request was denied as not covered and whose appeal was upheld for lack of medical necessity. Government plans, Medicare and individual-market policies are not ERISA employer plans. Nothing to sign up for: if a class is certified, notice comes from the court process. Keep your denial letters and appeal decisions.
Is There Any Zepbound Settlement Money?
The dollar ranges on law-firm websites are projections, not court figures. If the injury cases ever resolve, they would typically be valued case by case or on a grid weighing diagnosis, treatment and lasting harm — not split evenly.
The Caremark case is different: the complaint mainly asks the court to declare Zepbound medically necessary and order Caremark to reprocess denied coverage claims and issue plan benefits, plus other equitable relief. Even a win there may look like coverage decisions rather than a check. For settlements that are paying now, see our open class action settlements; to see how payouts are usually split, try the class action payout calculator.
How cases like this one end
Our copy of the federal courts’ own case database covers 166,050 health care/pharmaceutical product liability casesclosed in U.S. federal district courts between 2015 and 2025:
- 34.5% ended in a settlement recorded by the court. Another 17.9% were dismissed voluntarily, which often follows a private settlement — so the real settlement share sits between 34.5% and 52.4%.
- 9% were decided on a motion before any trial.
- 1 in 2,863 reached a trial (0%), after a median of 32 months.
- Median time from filing to the end of the case: 26.3 months.
- Almost none record a money award in this data (18 of 166,050), and the recorded figures are capped, so we do not publish an average.
These are base rates for this type of case (federal health care/pharmaceutical product liability cases) — not a prediction about this lawsuit, and not legal advice. Source: Federal Judicial Center, Integrated Database (civil), analysed by Settlement Insight. Cases heard in state courts are not included.
Zepbound Lawsuit Timeline
- 1
August 2023 — First GLP-1 Injury Suits
Patients begin suing Lilly and Novo Nordisk over alleged injuries from incretin drugs. Zepbound later joins Mounjaro and Trulicity on the list.
- 2
December 20, 2024 — Sleep Apnea Approval
Zepbound becomes the first FDA-approved drug for moderate-to-severe obstructive sleep apnea in adults with obesity, per the Caremark complaint.
- 3
July 1, 2025 — Caremark Drops Zepbound
The complaint alleges Caremark stops covering Zepbound under a Wegovy rebate deal with Novo Nordisk.
- 4
September 3, 2025 — Coverage Class Action Filed
Larkin v. Caremark Rx is filed in the Southern District of New York under ERISA, No. 1:25-cv-07307.
- 5
August 2026 — Caremark Must Defend
Judge Louis L. Stanton rules the plaintiffs validly alleged plan violations and self-dealing; the case moves forward.
- 6
September 14–18, 2026 — Expert Hearing
Rule 702 hearing set in MDL 3094. As of October 5, 2026, no ruling appears on the court’s orders list; 4,025 cases were pending on October 1.
Three Things to Watch For
Heavy advertising and a popular drug make the Zepbound lawsuit an easy hook:
“Claim your Zepbound settlement payment”
There is no Zepbound settlement and no claim portal. A text or site asking for your pharmacy records, insurance ID or bank details to “release your share” is collecting data, not paying claims.
Cheap “Zepbound” from the same ads
Be wary of pages that pair Zepbound lawsuit news with offers of compounded tirzepatide, tablets or drops. Lilly’s lawsuits against telehealth sellers allege some of these versions were never studied. A lawsuit page that also sells you the drug is a sales funnel.
Callers who know you were denied coverage
Caremark’s formulary change affected plan members across the country, so a caller who mentions your denial proves nothing. No court process phones you for a fee or your full Social Security number to join the Caremark case.
Zepbound Lawsuit — Questions People Actually Ask
Is there a Zepbound settlement?
No. As of October 5, 2026, there is no Zepbound settlement in the injury MDLs or in the Caremark coverage case — no fund, no administrator, no claim form and no deadline.
What is the Zepbound lawsuit about?
Two things. Injury lawsuits allege Lilly failed to warn about stomach and bowel problems or vision loss linked to GLP-1 drugs including Zepbound. A separate class action alleges CVS Caremark wrongly stopped covering Zepbound on July 1, 2025 to favor Wegovy under a rebate deal.
How many Zepbound lawsuits are there?
The court does not count Zepbound separately. On October 1, 2026, the GLP-1 stomach-injury MDL had 4,025 pending cases and the vision-loss MDL had 247, across all manufacturers. See our GLP-1 lawsuit overview.
Is Zepbound part of the Mounjaro and Ozempic lawsuits?
Yes. Zepbound and Mounjaro contain the same drug, tirzepatide, and injury claims over both sit in the same Philadelphia MDLs as Ozempic and Wegovy claims. Details: Mounjaro lawsuit.
What happened at the September 2026 hearing?
Judge Karen S. Marston scheduled a Rule 702 (“Daubert”) hearing for September 14–18, 2026 to test whether the plaintiffs’ expert evidence is reliable enough for a jury. As of October 5, 2026, no ruling appears on the court’s orders list.
My plan stopped covering Zepbound. Am I in the CVS Caremark case?
Possibly, if your employer plan is governed by ERISA, uses Caremark, denied Zepbound as not covered and upheld that on appeal for lack of medical necessity. No class has been certified, so for now nobody is formally a class member and there is nothing to file.
Do I need to do anything now?
If you were injured, injury claims are filed individually and state deadlines apply, so speak to a licensed attorney sooner rather than later. If you were denied coverage, keep your denial and appeal letters. Report side effects to your doctor.
Is the Eli Lilly case over the generic Zepbound something I can join?
No. In July 2026 Lilly said generic makers had filed applications to copy Mounjaro and Zepbound and that it intends to sue for patent infringement. That is a dispute between companies. More on Lilly’s other cases: Eli Lilly lawsuit.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.